Nucleis, RNAx Ink shRNA Technology Co-Marketing Deal
Nucleis, which develops custom transgenic mice, has signed a deal to co-market in vitro and in vivo shRNA validation technology with RNAx, the companies said this week.
Under the deal, RNAx will provide Nucleis and its customers with in vitro shRNA validation technology for use with its transgenic animal generation technology. Nucleis and its customers will, in exchange, allow RNAx to use the transgenic animal generation technology in conjunction with its shRNA validation technology.
The companies said the goal of the arrangement is to provide both firms' customers with the two technologies from a single source. Financial terms of the arrangement were not disclosed.
TNO, Mitsubishi Ink siRNA Technology Development Deal
TNO and Mitsubishi Pharma said this week that they have formed an siRNA in vivo technology development collaboration.
Under the deal, TNO will combine its siRNA technology and disease model expertise to characterize a set of Mitsubishi's proprietary disease targets.
Financial terms of the arrangement were not disclosed.
CytRx HIV Vaccine Appears Well Tolerated, Potentially Effective in Phase I
CytRx said this week that interim results from a phase I study of the company's DNA- and protein-based HIV vaccine indicate that the drug was well-tolerated, stimulated immune cells, and produced antibody responses with neutralizing activity against multiple HIV strains.
"Based on the strength of these preliminary results, we are already considering further clinical development, as we believe that [the drug, which is called] DP6-001, is a potential breakthrough vaccine," CytRx President and CEO Steven Kriegsman said in a statement. "If the final analysis confirms these interim findings, it may facilitate our ability to compete for external methods of financing next phase clinical development of the vaccine through grants or corporate alliances."
Invitrogen and Scripps Research Institute to Co-Develop Methods for Studying Membrane Proteins
Invitrogen and the Scripps Research Institute are collaborating on new methods to study membrane proteins, the partners said last month.
Under the direction of Geoffrey Chang, a group leader at Scripps, scientists at Scripps and Invitrogen's proteomics R&D group will try to develop better ways to express, isolate, and characterize membrane proteins.
Invitrogen will have the right to commercialize resulting technologies in the research and drug-screening markets.
Invitrogen to Market, Distribute Nonlinear Dynamics' Proteomics Software
Invitrogen said last month that it will market and distribute a number of products from Nonlinear Dynamics' TotalLab and Progenesis lines.
Terms of the deal call for the products, which include tools for 1D and 2D electrophoresis-gel analysis, to be marketed with Invitrogen's proteomics technologies, especially the firm's own 1D and 2D gel electrophoresis line.
The companies said they plan to "work together to integrate further" other product lines.